Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Bought by Victory Capital Management Inc.

Victory Capital Management Inc. increased its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 34.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 88,808 shares of the biotechnology company's stock after acquiring an additional 22,529 shares during the period. Victory Capital Management Inc. owned about 0.09% of Sarepta Therapeutics worth $10,798,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in SRPT. Manchester Capital Management LLC lifted its holdings in shares of Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after buying an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Sarepta Therapeutics by 169.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock valued at $30,000 after buying an additional 156 shares during the period. Sunbelt Securities Inc. lifted its holdings in shares of Sarepta Therapeutics by 446.2% during the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock valued at $35,000 after buying an additional 232 shares during the period. Huntington National Bank lifted its holdings in shares of Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock valued at $36,000 after buying an additional 175 shares during the period. Finally, Newbridge Financial Services Group Inc. bought a new position in shares of Sarepta Therapeutics during the 4th quarter valued at $36,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Insider Buying and Selling

In related news, Director Claude Nicaise sold 2,491 shares of the company's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares of the company's stock, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 7.70% of the company's stock.

Sarepta Therapeutics Price Performance

Shares of SRPT traded down $1.18 during mid-day trading on Friday, hitting $97.19. 874,067 shares of the company were exchanged, compared to its average volume of 916,983. Sarepta Therapeutics, Inc. has a 1-year low of $97.06 and a 1-year high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The company has a 50 day moving average of $111.73 and a 200-day moving average of $120.10. The stock has a market cap of $9.43 billion, a price-to-earnings ratio of 77.75 and a beta of 0.79.

Analyst Upgrades and Downgrades

SRPT has been the topic of several research analyst reports. HC Wainwright reissued a "sell" rating and set a $75.00 price target on shares of Sarepta Therapeutics in a report on Thursday, February 27th. Needham & Company LLC reaffirmed a "buy" rating and issued a $202.00 target price on shares of Sarepta Therapeutics in a report on Thursday, February 27th. Royal Bank of Canada decreased their target price on Sarepta Therapeutics from $165.00 to $161.00 and set an "outperform" rating on the stock in a report on Thursday, February 27th. Piper Sandler cut their price target on Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating for the company in a research note on Wednesday, November 27th. Finally, Scotiabank began coverage on Sarepta Therapeutics in a research note on Friday, March 7th. They issued a "sector perform" rating and a $105.00 price target for the company. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $170.41.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.